Omeros stock tumbles after EU panel rejects Yartemlea

Investing.com -- Omeros Corporation (NASDAQ: OMER) fell 14% Friday morning after the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion for Yartemlea.

The CHMP recommended against approval of Yartemlea (narsoplimab) for the treatment of adults and children from two years of age with haematopoietic stem cell transplant-associated thrombotic microangiopathy. Thrombotic microangiopathy is a serious and potentially life-threatening complication following HSCT, a procedure where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow that produces healthy cells.

The committee also adopted negative opinions for two other medicines: Tacquell (autologous melanoma-derived tumour infiltrating lymphocytes, ex vivo-expanded), for the treatment of advanced melanoma, and Xervyteg (allogeneic faecal microbiota, pooled), for the treatment of acute graft-versus-host disease.

You May Also Be Interested In

• FDA Committee Recommends To Widen Access To Bpc-157 Peptide
• SpaceX (SPCX) Is Turning Away Commercial Falcon Customers Beyond 2028 - Bloomberg
• RTX secures $42 million F-35 engine contract